Balyasny Asset Management
ALNY icon

Balyasny Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Balyasny Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,100
Closed -$437K – 2845
2025
Q4 		$437K Buy
1,100
+400
+57% +$177K ﹤0.01% 2575
2025
Q3 		$319K Sell
700
-600
-46% -$244K ﹤0.01% 2561
2025
Q2 		$424K Buy
1,300
+400
+44% +$111K ﹤0.01% 2354
2025
Q1 		$243K Sell
900
-2,100
-70% -$540K ﹤0.01% 2529
2024
Q4 		$706K Sell
3,000
-11,300
-79% -$2.97M ﹤0.01% 2075
2024
Q3 		$3.93M Buy
+14,300
New +$3.72M 0.01% 1375
2023
Q2 		– Sell
-325,000
Closed -$65.1M – 2237
2023
Q1 		$65.1M Buy
325,000
+312,000
+2,400% +$65.6M 0.16% 155
2022
Q4 		$3.09M Buy
+13,000
New +$2.77M 0.01% 1221
2022
Q1 		– Sell
-238,000
Closed -$40.4M – 2440
2021
Q4 		$40.4M Buy
238,000
+141,000
+145% +$26.2M 0.14% 191
2021
Q3 		$18.3M Sell
97,000
-122,300
-56% -$22.9M 0.08% 364
2021
Q2 		$37.2M Buy
219,300
+134,300
+158% +$19.7M 0.18% 132
2021
Q1 		$12M Buy
+85,000
New +$12.8M 0.06% 426
2020
Q2 		– Sell
-60,000
Closed -$6.53M – 1096
2020
Q1 		$6.53M Buy
+60,000
New +$6.93M 0.08% 339
2019
Q4 		– Sell
-50,000
Closed -$4.02M – 1142
2019
Q3 		$4.02M Buy
+50,000
New +$3.96M 0.03% 591

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's ALNY Position: Q1 2026 in Review

Balyasny Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,026 shares — an estimated $1.2M sold.

Balyasny Asset Management first reported a position in ALNY in Q2 2015 and held it in 24 quarters. The position peaked at $50.4M in Q1 2023. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Balyasny Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 3,026 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.2M.
  • Balyasny Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 24 quarters.
  • Balyasny Asset Management's Alnylam Pharmaceuticals position peaked at $50.4M in Q1 2023.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.